Hints and tips:
...Sure enough, by the end, an EpiPen has made an appearance and all hell has broken loose. The night is a record of every hardship that could possibly take place in a restaurant, including self-harm....
...Perhaps unsurprisingly, Wegovy — a weekly injection patients self-administer using a small device that looks a bit like an EpiPen — has plenty of fans. Patients like Robillard, for one....
...The Delta Air Lines plane had no EpiPen auto-injectors on board, but it did, in accordance with Federal Aviation Administration regulations, have epinephrine and a syringe....
...“If you live in a rural area, need your EpiPen shot and the closest hospital is two hours away, it’s a matter of life and death — a drone could get to you far more efficiently,” she said....
...This is best known for manufacturing generic drugs, as well as Epipens. Mylan shares have fallen by more than half in the past two years.* The generics sector has lost much of its pricing power....
...It also caused controversy by dramatically raising the price of EpiPens, used to treat allergic reactions....
...Mylan had previously come under scrutiny over rising EpiPen prices....
...But she came under fire in 2016 for raising the price of Mylan’s popular EpiPen treatment for allergic reactions by 5,000 per cent over nine years, contributing to a public backlash against drugmakers....
...There is a worldwide shortage of EpiPens. Many pharmacists have run out just as parents need EpiPens to send to their children’s schools at the start of a new year....
...Pennsylvania-headquartered Mylan later lowered the EpiPen’s price tag....
...The shortage of EpiPens is particularly irksome for Mylan as it tries to move on from controversy over the cost of the medicine....
...The company credited that to “significantly lower volume” for existing products, including EpiPen Earnings tumbled, dropping to $37.5m, or 7 cents a share, from $297m, or 55 cents a year ago....
...Here are five lapses by Mylan, the company that owns the rights to the EpiPen, and the regulators who were meant to be monitoring them....
...His daughter, Heather Bresch, is chief executive of Mylan, the pharmaceutical company which attained notoriety in 2016 for having raised the price of EpiPen, the adrenaline auto-injector used to treat anaphylactic...
...Comical ferocities abound, including that much-reported moment with a blackberry allergy and an Epipen....
...The 2016 Epipen and Daraprim drug pricing scandals — in which costs were sharply increased over a short period, with the reputational backlash hitting companies’ share prices — resulted in regulatory and...
...The guidance tweaks comes as Mylan continues to do battle with price pressure on generic drugs in the US and falling demand for its blockbuster emergency allergy shot EpiPen....
...The launch of rival products has forced Mylan to offer large discounts on the EpiPen to the pharmacy benefit managers that negotiate drug prices in the US, the pharmaceuticals group said....
...The list of villains included Martin Shkreli, the disgraced biotech entrepreneur, Valeant, the Canadian drugmaker, and Mylan, the maker of the EpiPen allergy shot....
...The EpiPen uproar hurt Mylan’s shares, which declined almost 30 per cent during 2016....
...The company also said sales of its EpiPen allergy injection, which made global headlines for its high price, had declined in the quarter due to increased competition. Image: Reuters...
...Mylan pumped up the price of EpiPen, for bee-sting allergies, by 500 per cent over six years. Valeant, a one-time stock market darling, made price gouging a core strategy. The list goes on....
...A handful of individuals objected to serving on the jury because of what they thought about price increases involving the EpiPen, an anti-allergy device, even though Mr Shkreli had no involvement with it...
...US lawmakers have set their sights over the past year on rising drug prices, with rival drugmakers like Mylan — the maker of EpiPen — facing criticism over how much patients must spend on potentially life-saving...
...But, he added that he did not expect the EpiPen to face major outside competition before the second half of 2017 at the earliest....
International Edition